Search

Your search keyword '"Qin,Shukui"' showing total 955 results
Start Over Author "Qin,Shukui"
955 results on '"Qin,Shukui"'

2. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Author

Wainberg, Zev, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, and Enzinger, Peter

Subjects
Bemarituzumab, FGFR2b, Gastric cancer, Targeted therapy, mFOLFOX6, Humans, Stomach Neoplasms, Fluorouracil, Receptor, Fibroblast Growth Factor, Type 2, Adenocarcinoma, Esophagogastric Junction, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized
Abstract

BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. RESULTS: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. CONCLUSIONS: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626). CLINICAL TRIAL REGISTRATION: NCT03694522.

Published
2024

3. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Author

Wang, Feng, Shen, Lin, Guo, Weijian, Liu, Tianshu, Li, Jin, Qin, Shukui, Bai, Yuxian, Chen, Zhendong, Wang, Jufeng, Pan, Yueyin, Shu, Yongqian, Zhao, Fuyou, Cheng, Ying, Ye, Feng, Gu, Kangsheng, Zhang, Tao, Pan, Hongming, Zhong, Haijun, Zhou, Fuxiang, Qin, Yanru, Yang, Lei, Mao, Weidong, Li, Qiu, Dai, Wenxiang, Li, Wei, Wang, Shubin, Tang, Yong, Ma, Dong, Yin, Xianli, Deng, Yanhong, Yuan, Ying, Li, Man, Hu, Wenwei, Chen, Donghui, Li, Guoxin, Liu, Qiqi, Tan, Panfeng, Fan, Songhua, Shi, Michael, Su, Weiguo, and Xu, Rui-Hua

Published
2024
Full Text
View/download PDF

4. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Author

Li, Jin, Bai, Yuxian, Chen, Zhendong, Ying, Jieer, Guo, Yabing, Fang, Weijia, Zhang, Feng, Xiong, Jianping, Zhang, Tao, Meng, Zhiqiang, Zhang, Jingdong, Ren, Zhenggang, Hao, Chunyi, Chen, Yajin, Lin, Xiaoyan, Pan, Hongming, Zhou, Fuxiang, Li, Xin, Yu, Fan, Zhang, Juan, Zhang, Zhang, and Qin, Shukui

Published
2024
Full Text
View/download PDF

5. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial

Author

Cui, Jiujie, Qin, Shukui, Zhou, Yuhong, Zhang, Shuang, Sun, Xiaofeng, Zhang, Mingjun, Cui, Jiuwei, Fang, Weijia, Gu, Kangsheng, Li, Zhihua, Wang, Jufeng, Chen, Xiaobing, Yao, Jun, Zhou, Jun, Wang, Gang, Bai, Yuxian, Xiao, Juxiang, Qiu, Wensheng, Wang, Bangmao, Xia, Tao, Wang, Chunyue, Kong, Li, Yin, Jiajun, Zhang, Tao, Shen, Xionghu, Fu, Deliang, Gao, Chuntao, Wang, Huan, Wang, Quanren, and Wang, Liwei

Published
2024
Full Text
View/download PDF

6. Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

Author

Kudo, Masatoshi, Chan, Stephen Lam, Sangro, Bruno, Erinjeri, Joseph P., Qin, Shukui, Ren, Zhenggang, Arai, Yasuaki, Breder, Valeriy Vladimirovich, Lin, Shi-Ming, Peron, Jean-Marie, Nguyen, Tien Quang, Yan, Lunan, Chiu, Chang-Fang, Santos, Florinda A., Veluvolu, Anil, Thungappa, Satheesh Chiradoni, Morgan, Claire, Parsons, Kerry, Xynos, Ioannis, and Lencioni, Riccardo

Published
2024
Full Text
View/download PDF

7. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Author

Oh, Do-Youn, He, Aiwu Ruth, Bouattour, Mohamed, Okusaka, Takuji, Qin, Shukui, Chen, Li-Tzong, Kitano, Masayuki, Lee, Choong-kun, Kim, Jin Won, Chen, Ming-Huang, Suksombooncharoen, Thatthan, Ikeda, Masafumi, Lee, Myung Ah, Chen, Jen-Shi, Potemski, Piotr, Burris, Howard A, III, Ostwal, Vikas, Tanasanvimon, Suebpong, Morizane, Chigusa, Zaucha, Renata E, McNamara, Mairéad G, Avallone, Antonio, Cundom, Juan E, Breder, Valeriy, Tan, Benjamin, Shimizu, Satoshi, Tougeron, David, Evesque, Ludovic, Petrova, Mila, Zhen, David B, Gillmore, Roopinder, Gupta, Vineet Govinda, Dayyani, Farshid, Park, Joon Oh, Buchschacher, Gary L, Jr, Rey, Felipe, Kim, Hyosung, Wang, Julie, Morgan, Claire, Rokutanda, Nana, Żotkiewicz, Magdalena, Vogel, Arndt, and Valle, Juan W

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Author

Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Jiang, Da, Zhang, Guifang, He, Yifu, Ba, Yi, Zhong, Haijun, Wang, Lin, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Wu, Xiangyuan, Gao, Feng, Sun, Guogui, Wu, Yongjuan, Ye, Feng, Wang, Qiong, Xie, Zhong, Yi, Tienan, Huang, Yong, Yu, Guohua, Lu, Lin, Yuan, Ying, Li, Wei, Liu, Likun, Sun, Yuping, Sun, Ying, Yin, Lifeng, and Hou, Zhiguo

Published
2023
Full Text
View/download PDF

9. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

Author

Hu, Xingsheng, Zhang, Shucai, Ma, Zhiyong, Feng, Jifeng, Wu, Lin, Lv, Dongqing, Zhou, Jianying, Zhang, Xiaodong, Liu, Li, Yu, Qitao, Liao, Wangjun, Zhang, Yiping, Wang, Xiang, Cheng, Ying, Niu, Hongrui, Wang, Ziping, Wang, Dong, Huang, Cheng, Liu, Chunling, Zhao, Hui, Feng, Jian, Li, Jingzhang, Ying, Kejing, Yang, Nong, Qin, Shukui, Hu, Jie, Liu, Fei, Jiang, Yong, Ge, Nan, and Shi, Yuankai

Published
2023
Full Text
View/download PDF

10. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Author

Yau, Thomas, Kaseb, Ahmed, Cheng, Ann-Lii, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Milwee, Steven, Wang, Zhong, Curran, Dominic, Kelley, Robin Kate, and Rimassa, Lorenza

Published
2024
Full Text
View/download PDF

11. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Author

Kelley, Robin Kate, Sangro, Bruno, Harris, William, Ikeda, Masafumi, Okusaka, Takuji, Kang, Yoon-Koo, Qin, Shukui, Tai, David W-M, Lim, Ho Yeong, Yau, Thomas, Yong, Wei-Peng, Cheng, Ann-Lii, Gasbarrini, Antonio, Damian, Silvia, Bruix, Jordi, Borad, Mitesh, Bendell, Johanna, Kim, Tae-You, Standifer, Nathan, He, Philip, Makowsky, Mallory, Negro, Alejandra, Kudo, Masatoshi, and Abou-Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, HIV/AIDS, Orphan Drug, Rare Diseases, Cancer, Biotechnology, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Liver Cancer, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThis phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).Patients and methodsPatients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles.ResultsA total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively.ConclusionAll regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.

Published
2021

12. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyBiomarker Analysis Following Lenvatinib in Unresectable HCC

Author

Finn, Richard S, Kudo, Masatoshi, Cheng, Ann-Lii, Wyrwicz, Lucjan, Ngan, Roger KC, Blanc, Jean-Frederic, Baron, Ari D, Vogel, Arndt, Ikeda, Masafumi, Piscaglia, Fabio, Han, Kwang-Hyub, Qin, Shukui, Minoshima, Yukinori, Kanekiyo, Michio, Ren, Min, Dairiki, Ryo, Tamai, Toshiyuki, Dutcus, Corina E, Ikezawa, Hiroki, Funahashi, Yasuhiro, and Evans, Thomas R Jeffry

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Clinical Research, Antineoplastic Agents, Biomarkers, Tumor, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Phenylurea Compounds, Predictive Value of Tests, Quinolines, Sorafenib, Survival Rate, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeIn REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and efficacy outcomes from REFLECT.Experimental designSerum biomarkers (VEGF, ANG2, FGF19, FGF21, and FGF23) were measured by ELISA. Gene expression in tumor tissues was measured by the nCounter PanCancer Pathways Panel. Pharmacodynamic changes in serum biomarker levels from baseline, and associations of clinical outcomes with baseline biomarker levels, were evaluated.ResultsFour hundred and seven patients were included in the serum analysis set (lenvatinib n = 279, sorafenib n = 128); 58 patients were included in the gene-expression analysis set (lenvatinib n = 34, sorafenib n = 24). Both treatments were associated with increases in VEGF; only lenvatinib was associated with increases in FGF19 and FGF23 at all time points. Lenvatinib-treated responders had greater increases in FGF19 and FGF23 versus nonresponders at cycle 4, day 1 (FGF19: 55.2% vs. 18.3%, P = 0.014; FGF23: 48.4% vs. 16.4%, P = 0.0022, respectively). Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups. OS was longer for lenvatinib than sorafenib [median, 10.9 vs. 6.8 months, respectively; HR, 0.53; 95% confidence interval (CI), 0.33-0.85; P-interaction = 0.0397] with higher baseline FGF21. In tumor tissue biomarker analysis, VEGF/FGF-enriched groups showed improved OS with lenvatinib versus the intermediate VEGF/FGF group (HR, 0.39; 95% CI, 0.16-0.91; P = 0.0253).ConclusionsHigher baseline levels of VEGF, FGF21, and ANG2 may be prognostic for shorter OS. Higher baseline FGF21 may be predictive for longer OS with lenvatinib compared with sorafenib, but this needs confirmation.

Published
2021

13. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

15. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H

Published
2023
Full Text
View/download PDF

16. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

17. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Author

Qin, Shukui, Chan, Stephen L, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Zhang, Mingxiang, Xu, Li, Yuan, Xianglin, Li, Da, Ying, Jierer, Zhang, Jingdong, Zhang, Tao, Gu, Kangsheng, He, Yifu, Hao, Ping, Jiang, Da, Zhang, Shu, Xing, Baocai, Zhang, Baihong, Wang, Dong, Zhai, Xiaofeng, Liang, Houjie, Cybulska-Stopa, Bozena, Dvorkin, Mikhail, Stroyakovskiy, Daniil, Nechaeva, Marina, Yen, Chia-Jui, Su, Wei-Wen, Chen, Yen-Hao, Bondarenko, Igor, Yang, Lin, Fang, Weijia, Gomez-Martin, Carlos, Ryu, Min-Hee, Kim, Han-Sang, Kim, Jee-Hyun, Zarubenkov, Oleg, Orlova, Rashida, Poddubskaya, Elena, Fadeeva, Natalia, Makarova, Yulia, Chao, Yee, Hung, Chao-Hung, Neffa, Maryna, Vynnychenko, Oleksandr, Burgoyne, Adam, Hao, Chunyi, Mohr, Raphael U, Diaz-Beveridge, Roberto, Feliu-Batlle, Jaime, Cubillo-Gracian, Antonio, Lee, Ann-Shing, Daniele, Bruno, Antonuzzo, Lorenzo, Sangiovanni, Angelo, Gasbarrini, Antonio, Scartozzi, Mario, Ahn, Mi Sun, Oh, Sung-Yong, Orlov, Sergey, Harputluoglu, Hakan, Oksuzoglu, Berna, Hsu, Chiun, Rau, Kun-Ming, Krechkovskyi, Oleksandr, Yareshko, Vladimir, Xiong, Henry, Lee, Fa-Chyi, Jiang, Yixing, Gabayan, Afshin, Crow, Mary, Van Steenkiste, Christophe, and Verset, Gontran

Published
2023
Full Text
View/download PDF

19. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Author

Carranza, Omar, Greco, Martin Alberto, Coward, Jim, Joshua, Anthony, Karapetis, Christos, Hart, Christopher, Zhang, Alison, Prenen, Hans, Goeminne, Jean-Charles, Machiels, Jean-Pascal, Rottey, Sylvie, Corassa, Marcelo, Molin, Graziela Zibetti Dal, Tiscoski, Katsuki, Jardim, Denis Leonardo Fontes, Mak, Milena, Fu, Wei, Yao, Herui, Huang, Jing, Jiang, Haiping, Qin, Shukui, Chen, Baoshi, Yan, Dong, Yang, Yu, Loriot, Yohann, Le Tourneau, Christophe, Penel, Nicolas, Salas, Sébastien, Blay, Jean-Yves, Brachet, Pierre-Emmanuel, Durando, Xavier, Emambux, Sheik, Ravaud, Alain, Folprecht, Gunnar, Arnold, Dirk, Schuler, Martin, Ahrens, Marit, Golf, Alexander, Haag, Georg Martin, Lordick, Florian, Desuki, Alexander, Cazzaniga, Marina, Ciardiello, Fortunato, Milella, Michele, Koyama, Takafumi, Hirooka, Yoshiki, Okamoto, Wataru, Aogi, Kenjiro, Kuboki, Yasutoshi, Lee, Jungyun, Kim, Sung-Bae, Ahn, Myung-Ju, Chang, Jong Hee, Kim, Yong-Man, Nam, Do-Hyun, Park, Jae-Sung, Lugowska, Iwona, Paz-Ares, Luis, Moreno, Victor, Cervantes, Andres, Calvo, Mariona, Falcon, Alejandro, Gonzalez, Antonio, Tabernero, Josep, Martinez Bueno, Alejandro, García-Corbacho, Javier, Longo, Federico, Yen, Chia-Jui, Chen, Jen-Shi, Hou, Ming-Feng, Chao, Yee, Rau, Kun-Ming, Chiu, Tai-Jan, Feng, Yin-Hsun, Hsu, Chih-Hung, Huang, Wen-Tsung, Lai, Kuan-Ming, Yeh, Su-peng, Palmer, Daniel, Minchom, Anna, Winter, Helen, Welsh, Liam, Plummer, Ruth, Iyer, Gopakumar, Gutierrez, Martin, Bilen, Mehmet, Arrowsmith, Edward, Pant, Shubham, Spigel, David Robert, Zandberg, Dan Paul, Doroshow, Deborah, Lu-Emerson, Christine, Moezi, Mehdi, Paulson, Scott, Reardon, David, Ward, Patrick, Chaves, Jorge, Grigg, Claud, Hussein, Atif, Manda, Sudhir, Monticelli, Michael, Qamar, Rubina, Richey, Stephen L, Tamura, David, Wilks, Sharon, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Reardon, David A, Massard, Christophe, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, and Sweiti, Hussein

Published
2023
Full Text
View/download PDF

20. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Akce, Mehmet, Ales Diaz, Inmaculada, Alves, Gustavo, Anand, Sumitra, Arslan, Cagatay, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Bai, Li-Yuan, Bai, Yuxian, Barajas, Olga, Bates, Susan, Begbie, Stephen, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Blanc, Jean-Frederic, Borbath, Ivan, Bordonaro, Robert, Bouattour, Mohamed, Brandi, Giovanni, Burgoyne, Adam, Butthongkomvong, Kritiya, Camandaroba, Marcos, Cao, Ke, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Ming-Huang, Chen, Xiaoming, Cheng, Ashley, Chiu, Tai-Jan, Choi, Hye Jin, Chon, Hong Jae, Collignon, Joelle, Cubillo Gracian, Antonio, Davis, Sarah, de Carvalho, Ricardo Saraiva, de Groot, D.J.A., Demols, Anne, De Vos, Judith, Diab, Maria, Easaw, Jacob, Eatock, Martin, Edeline, Julien, Elias, Rawad, Eskens, Fredericus, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Gbolahan, Olumide, Geboes, Karen, Geneser, Keri-Lee, Geng, Zhimin, Geva, Ravit, Gillmore, Roopinder, Goetze, Thorsten, Gou, Hongfeng, Grasselli, Julieta, Gu, Shanzhi, Gumus, Mahmut, Haj Mohammad, Nadia, Hao, Chunyi, Harputluoglu, Hakan, Hatoum, Hassan, Heinemann, Volker, Ho, Wang Kwong, Hsu, Chiun, Hubert, Ayala, Hwang, Juneul, Inanc, Mevlude, Iseas, Soledad, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Joubert, Warren, Juengsamarn, Jitlada, Kaen, Diego, Kanai, Masashi, Kasper-Virchow, Stefan, Kazemi, Ghazaleh, Kelleher, Fergal, Kelley, Robin, Kim, Jin Won, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Klumpen, Heinz, Kochenderfer, Mark, Kose, Fatih, Lam, Ho Ching, Lee, Choong-kun, Lee, Hyun Woo, Lee, Margaret, Lee, Myung Ah, Lee, Wai Man Sarah, Le Sourd, Samuel, Li, Dongliang, Li, Wei, Liang, Houjie, Liang, Tingbo, Lim, Chun Sen, Lingerfelt, Brian, Lopez, Charles, Low, John, Macarulla Mercade, Teresa, Malka, David, Mao, Yimin, Masi, Gianluca, McCune, Steven, McDermott, Ray, McWhirter, Elaine, Mendez, Guillermo, Milella, Michele, Mizuno, Nobumasa, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Nervi, Bruno, Ngamphaiboon, Nuttapong, Oh, Sang Cheul, Oksuzoglu, Berna, Outlaw, Darryl, Ozaka, Masato, Ozguroglu, Mustafa, Ozyilkan, Ozgur, Painemal, Claudio, Pan, Yueyin, Park, Joon Oh, Pelzer, Uwe, Peng, Chuang, Petorin, Caroline, Pezet, Denis, Power, Derek, Qin, Shukui, Ren, Zhenggang, Roohullah, Aflah, Ryu, Hyewon, Salman, Pamela, Sasaki, Mitsuhito, Sasidharan, Rita, Satoh, Taroh, Schulze, Kornelius, Scott-Brown, Martin, Segovia, Ruben, Seufferlein, Thomas, Siena, Salvatore, Sinapi, Isabelle, Smolenschi, Cristina, Song, Tianqiang, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Stemmer, Salomon, Su, Haichuan, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tan, Chih Kiang, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tortora, Giampaolo, Tsuji, Akihito, Ueno, Makoto, Uribe, Rodrigo, Venerito, Marino, Verdaguer Mata, Helena, Verslype, Chris, Victorino, Ana Paula, Vogel, Arndt, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Wasan, Harpeet, Weschenfelder, Rui, Wong, Chun Yin, Wong, Yoke Fui, Yalcin, Suayib, Yanez Weber, Patricio, Yang, Xuezhong, Yasui, Hisateru, Yau, Thomas, Yazici, Ozan, Yen, Chia-Jui, Ying, Jieer, Yoo, Changhoon, Yu, Wenchang, Zhao, Haitao, Kelley, Robin Kate, Finn, Richard S, Klümpen, Heinz-Josef, Chan, Stephen L, Valle, Juan W, Yu, Li, Malhotra, Usha, and Siegel, Abby B

Published
2023
Full Text
View/download PDF

22. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)

Author

Sheng, Xinan, Ye, Dingwei, Zhou, Aiping, Yao, Xin, Luo, Hong, He, Zhisong, Wang, Zengjun, Zhao, Yingchao, Ji, Zhigang, Zou, Qing, He, Chaohong, Guo, Jianming, Tu, Xinhua, Liu, Ziling, Shi, Benkang, Liu, Ben, Chen, Peng, Wei, Qiang, Hu, Zhiquan, Zhang, Yanqiao, Jiang, Kui, Zhou, Fangjian, Wu, Dapeng, Fu, Cheng, Li, Xingya, Wu, Bin, Wang, Lijie, Qin, Shukui, Li, Gang, Liu, Yunpeng, Guo, Hongqian, Chen, Kehe, Zhang, Dahong, Wang, Gongxian, Ding, Lieming, Wang, Yang, Yuan, Xiaobin, and Guo, Jun

Published
2023
Full Text
View/download PDF

23. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Author

Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Vogel, Arndt, Tovoli, Francesco, Ueshima, Kazuomi, Aikata, Hiroshi, López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E., and Lencioni, Riccardo

Published
2023
Full Text
View/download PDF

24. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Author

Galle, Peter Robert, primary, Decaens, Thomas, additional, Kudo, Masatoshi, additional, Qin, Shukui, additional, Fonseca, Leonardo, additional, Sangro, Bruno, additional, Karachiwala, Hatim, additional, Park, Joong-Won, additional, Gane, Edward, additional, Pinter, Matthias, additional, Tai, David, additional, Santoro, Armando, additional, Pizarro, Gonzalo, additional, Chiu, Chang-Fang, additional, Schenker, Michael, additional, He, Aiwu Ruth, additional, Wang, Qi, additional, Stromko, Caitlyn, additional, Hreiki, Joseph, additional, and Yau, Thomas, additional

Published
2024
Full Text
View/download PDF

25. GS-005 mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma

Author

Sangro, Bruno, primary, Kudo, Masatoshi, additional, Erinjeri, Joseph, additional, Qin, Shukui, additional, Ren, Zhenggang, additional, Chan, Stephen, additional, Arai, Yasuaki, additional, Heo, Jeong, additional, Mai, Ahn, additional, Escobar, Jose, additional, Chuken, Yamil Alonso Lopez, additional, Yoon, Jung-Hwan, additional, Tak, Won Young, additional, Suttichaimongkol, Tanita, additional, Bouattour, Mohamed, additional, Lin, Shi-Ming, additional, Żotkiewicz, Magdalena, additional, Ali, Sajid, additional, Cohen, Gordon, additional, and Lencioni, Riccardo, additional

Published
2024
Full Text
View/download PDF

26. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer

Author

Cui, Jiujie, Jiao, Feng, Li, Qi, Wang, Zheng, Fu, Deliang, Liang, Jun, Liang, Houjie, Xia, Tingyi, Zhang, Tao, Zhang, Yang, Dai, Guanghai, Zhang, Zhihong, Wang, Jian, Bai, Yongrui, Bai, Yuxian, Bi, Feng, Chen, Donghui, Cao, Dan, Chen, Jie, Fang, Weijia, Gao, Yong, Guo, Jianwei, Hao, Jihui, Hua, Haiqing, Huang, Xinyu, Liu, Wenchao, Liu, Xiufeng, Li, Da, Li, Ji, Li, Enxiao, Li, Zhiwei, Pan, Hongming, Shen, Lin, Sun, Yongwei, Tao, Min, Wang, Chengfeng, Wang, Fenghua, Xiong, Jianping, Zhang, Taiping, Zhang, Xuebin, Zhan, Xianbao, Zheng, Leizhen, Ren, Gang, Zhang, Tingting, Zhou, Jun, Ma, Qingyong, Qin, Shukui, Hao, Chunyi, and Wang, Liwei

Published
2022
Full Text
View/download PDF

27. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

Author

Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, and Qin, Shukui

Published
2022
Full Text
View/download PDF

28. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Author

Wainberg, Zev A, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, and Lee, Keun-Wook

Published
2022
Full Text
View/download PDF

29. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Author

Kelley, Robin Kate, Rimassa, Lorenza, Cheng, Ann-Lii, Kaseb, Ahmed, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Banerjee, Kamalika, Hazra, Saswati, Fawcett, Jonathan, and Yau, Thomas

Published
2022
Full Text
View/download PDF

30. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Author

Chan, Stephen L., Schuler, Martin, Kang, Yoon-Koo, Yen, Chia-Jui, Edeline, Julien, Choo, Su Pin, Lin, Chia-Chi, Okusaka, Takuji, Weiss, Karl-Heinz, Macarulla, Teresa, Cattan, Stéphane, Blanc, Jean-Frederic, Lee, Kyung-Hun, Maur, Michela, Pant, Shubham, Kudo, Masatoshi, Assenat, Eric, Zhu, Andrew X., Yau, Thomas, Lim, Ho Yeong, Bruix, Jordi, Geier, Andreas, Guillén-Ponce, Carmen, Fasolo, Angelica, Finn, Richard S., Fan, Jia, Vogel, Arndt, Qin, Shukui, Riester, Markus, Katsanou, Vasiliki, Chaudhari, Monica, Kakizume, Tomoyuki, Gu, Yi, Porta, Diana Graus, Myers, Andrea, and Delord, Jean-Pierre

Published
2022
Full Text
View/download PDF

31. Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.

Author

Finn, Richard S., Kudo, Masatoshi, Barnes, Gisoo, Meyer, Tim, Boisserie, Frederic, Abdrashitov, Ramil, Chen, Yaxi, Li, Songzi, Zhu, Andrew X., Qin, Shukui, and Vogel, Arndt

Subjects
FATIGUE (Physiology), PHYSICAL mobility, QUALITY of life, VISUAL analog scale, HEPATOCELLULAR carcinoma
Abstract

Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primary endpoint of noninferiority in overall survival (OS). This analysis compared health-related quality-of-life (HRQOL) outcomes between the arms. Methods: Systemic therapy-naive adults with HCC were randomized 1:1 to receive tislelizumab (n = 342) or sorafenib (n = 332). HRQOL was assessed using EORTC QLQ-C30, QLQ-HCC18, and EQ-5D-5L. At cycles 4 and 6, a mixed model for repeated measures was performed using key-prespecified patient-reported outcome (PRO) endpoints of the QLQ-C30 and the QLQ-HCC18. Time to deterioration was analyzed with the Kaplan-Meier method using the PRO endpoints. Results: At cycles 4 and 6, patients in the tislelizumab arm had better HRQOL outcomes than the patients in the sorafenib arm per mean-change difference in GHS/QOL, QLQ-C30 physical functioning and fatigue, and QLQ-HCC18 symptom index; however, no differences for pain were observed. Patients in the tislelizumab arm had lower risk of deterioration in GHS/QOL (HR: 0.68; 95% CI: 0.49–0.94), QLQ-C30 physical functioning (HR: 0.45; 95% CI: 0.32–0.63) and fatigue (HR: 0.47; 95% CI: 0.36–0.61), QLQ-HCC18 symptom index (HR: 0.52; 95% CI: 0.34–0.81), and HCC-specific fatigue (HR: 0.59; 95% CI: 0.45–0.79). For pain, both arms had similar risk of deterioration (HR: 0.78; 95% CI: 0.56–1.09). At cycles 4 and 6, patients in the tislelizumab arm maintained in EQ-5D-5L visual analog scale, whereas scores decreased for the patients in the sorafenib arm. Conclusion: Patients with 1L HCC treated with tislelizumab had favorable HRQOL outcomes compared with patients treated with sorafenib, particularly in fatigue and physical functioning. These results, along with favorable safety profile, better response rate, and OS noninferiority, support tislelizumab as a potential 1L treatment option for unresectable HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT.

Author

Finn, Richard S., Qin, Shukui, Piscaglia, Fabio, Evans, Thomas R. Jeffry, Knox, Jennifer J., López López, Carlos, Ramji, Zahra, Ren, Min, Mody, Kalgi, Vogel, Arndt, and Kudo, Masatoshi

Subjects
CLINICAL trials, ADVERSE health care events, HEPATOCELLULAR carcinoma, OVERALL survival, ALPHA fetoproteins
Abstract

Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79–1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blinded independent imaging review (IIR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); per modified RECIST (mRECIST), the ORR was 40.6%. We sought to further characterize these tumor responses and explore ORR's importance among outcomes for patients with HCC. Methods: Efficacy assessments included all patients randomly assigned to receive lenvatinib treatment (if bodyweight ≥60 kg, 12 mg/day; if <60 kg, 8 mg/day). Time to first objective response (TTR) and duration of response (DOR) included patients who achieved a partial or complete tumor response. Tumors were assessed by IIR per RECIST v1.1 or mRECIST. Results: Four hundred seventy-eight patients were randomly assigned to receive lenvatinib. By IIR, 90 patients (18.8%) achieved an objective response per RECIST v1.1, and 194 (40.6%) had an objective response per mRECIST. Median TTR/DOR were 2.8 months/7.4 months in responders per RECIST v1.1, and 1.9 months/7.3 months in responders per mRECIST, respectively. Per baseline disease characteristics, ORRs by Child-Pugh score (A5/A6) were 21.2%/11.2% per RECIST v1.1 and 42.9%/33.6% per mRECIST, respectively. By baseline alpha-fetoprotein level (<400/≥400 ng/mL), ORRs were 21.4%/15.4% per RECIST v1.1 and 45.6%/33.8% per mRECIST, respectively. Incidences of treatment-related treatment-emergent adverse events were 98.9% in responders per RECIST v1.1 and 97.9% in responders per mRECIST. Conclusions: Responses were seen even in those patients with more severe disease at baseline. Tumor responses occurred early and were durable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial

Author

Xu, Rui-Hua, Zhang, Yanqiao, Pan, Hongming, Feng, Jifeng, Zhang, Tao, Liu, Tianshu, Qin, Yanru, Qin, Shukui, Yin, Xianli, Liu, Baorui, Ba, Yi, Yang, Nong, Voon, Pei Jye, Tanasanvimon, Suebpong, Zhou, Chan, Zhang, Wan Li, and Shen, Lin

Published
2021
Full Text
View/download PDF

35. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Author

Vogel, Arndt, Qin, Shukui, Kudo, Masatoshi, Su, Yun, Hudgens, Stacie, Yamashita, Tatsuya, Yoon, Jung-Hwan, Fartoux, Laetitia, Simon, Krzysztof, López, Carlos, Sung, Max, Mody, Kalgi, Ohtsuka, Tatsuroh, Tamai, Toshiyuki, Bennett, Lee, Meier, Genevieve, and Breder, Valery

Published
2021
Full Text
View/download PDF

36. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Author

Qin, Shukui, Li, Qiu, Gu, Shanzhi, Chen, Xiaoming, Lin, Lizhu, Wang, Zishu, Xu, Aibing, Chen, Xi, Zhou, Cuncai, Ren, Zhenggang, Yang, Lin, Xu, Li, Bai, Yuxian, Chen, Lei, Li, Jun, Pan, Hongming, Cao, Bangwei, Fang, Weijia, Wu, Wei, Wang, Ge, Cheng, Ying, Yu, Zhuang, Zhu, Xu, Jiang, Da, Lu, Yinying, Wang, Huaming, Xu, Jianming, Bai, Li, Liu, Yunpeng, Lin, Hailan, Wu, Changping, Zhang, Yang, Yan, Ping, Jin, Chunlei, and Zou, Jianjun

Published
2021
Full Text
View/download PDF

37. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Author

Galle, Peter R, Finn, Richard S, Qin, Shukui, Ikeda, Masafumi, Zhu, Andrew X, Kim, Tae-You, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed, Li, Daneng, Mulla, Sohail, Verret, Wendy, Xu, Derek-Zhen, Hernandez, Sairy, Ding, Beiying, Liu, Juan, Huang, Chen, Lim, Ho Yeong, Cheng, Ann-Lii, and Ducreux, Michel

Published
2021
Full Text
View/download PDF

38. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Author

Xu, Binghe, Yan, Min, Ma, Fei, Hu, Xichun, Feng, Jifeng, Ouyang, Quchang, Tong, Zhongsheng, Li, Huiping, Zhang, Qingyuan, Sun, Tao, Wang, Xian, Yin, Yongmei, Cheng, Ying, Li, Wei, Gu, Yuanting, Chen, Qianjun, Liu, Jinping, Cheng, Jing, Geng, Cuizhi, Qin, Shukui, Wang, Shusen, Lu, Jinsong, Shen, Kunwei, Liu, Qiang, Wang, Xiaojia, Wang, Hong, Luo, Ting, Yang, Jin, Wu, Yudong, Yu, Zhiyong, Zhu, Xiaoyu, Chen, Chunxia, and Zou, Jianjun

Published
2021
Full Text
View/download PDF

40. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

Author

Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

41. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Author

Kang, Yoon-Koo, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter, Wainberg, Zev, Kang, Yoon-Koo, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter, and Wainberg, Zev

Abstract

BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. RESULTS: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. CONCLUSIONS: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626). CLINICAL TRIAL REGISTRATION: NCT03694522.

Published
2024

43. A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.

Author

Qin, Shukui, Fang, Weijia, Ren, Zhenggang, Ou, Shuangyan, Lim, Ho Yeong, Zhang, Feng, Lee, Kin Chung, Choi, Hye Jin, Tong, Jiandong, Tao, Min, Xu, Aibing, Cheng, Ashley, Lu, Chang-Hsien, Chiu, Chang-Fang, Wahid, Mohamed Ibrahim Abdul, Kamble, Shital, Norquist, Josephine M., Zhong, Wenyan, Li, Chen, and Chen, Zhendong

Subjects
QUALITY of life, VISUAL analog scale, PATIENT reported outcome measures, HEPATOCELLULAR carcinoma, OVERALL survival
Abstract

Introduction: KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular carcinoma. We present results on health-related quality of life (HRQoL). Methods: HRQoL was evaluated using the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EuroQol-5D-3L (EQ-5D-3L) questionnaires. Key HRQoL endpoints were least squares mean (LSM) score changes from baseline to week 12 and time to deterioration (TTD) for EORTC QLQ-C30 global health status (GHS)/QoL. p values were one-sided and nominal without adjustment for multiplicity. Results: The HRQoL population included patients randomly assigned to pembrolizumab (n = 298) and placebo (n = 152). From baseline to week 12, a greater decline in EORTC QLQ-C30 GHS/QoL score was observed with placebo (LSM, −8.4; 95% CI: −11.7 to −5.1) versus pembrolizumab (−4.0; 95% CI: −6.4 to −1.6; difference vs. placebo: 4.4; 95% CI: 0.5–8.4; nominal p = 0.0142). Similarly, a greater decline in the EQ-5D-3L visual analog scale score was observed with placebo (−6.9; 95% CI: −9.4 to −4.5) versus pembrolizumab (−2.7; 95% CI: −4.5 to −1.0; difference vs. placebo: 4.2; 95% CI: 1.2–7.2; nominal p = 0.0030). TTD in EORTC QLQ-C30 GHS/QoL score was similar between arms (hazard ratio, 0.85; 95% CI: 0.58–1.25; nominal p = 0.1993). Conclusion: Patients receiving placebo showed a greater decline in HRQoL than those receiving pembrolizumab. Combined with efficacy and safety data from KEYNOTE-394 and the global KEYNOTE-240 and KEYNOTE-224 trials, our data support the clinically meaningful benefit and manageable tolerability of pembrolizumab as second-line therapy for patients with advanced hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study.

Author

Qin, Shukui, Wang, Yusheng, Yao, Jun, Liu, Yanyan, Yi, Tienan, Pan, Yueyin, Chen, Zhendong, Zhang, Xizhi, Lu, Jin, Yu, Junyan, Zhang, Yanjun, Cheng, Peng, Mao, Yong, Zhang, Jian, Fang, Meiyu, Zhang, Yanming, Lv, Jing, Li, Runzi, Dou, Ning, and Tang, Qian

Abstract

Background: Chemotherapy-induced thrombocytopenia (CIT) increases the risk of bleeding, necessitates chemotherapy dose reductions and delays, and negatively impacts prognosis. Objectives: This study aimed to evaluate the efficacy and safety of hetrombopag for the management of CIT in patients with advanced solid tumors. Design: A multicenter, randomized, double-blind, placebo-controlled, phase II study. Methods: Patients with advanced solid tumors who experienced a chemotherapy delay of ⩾7 days due to thrombocytopenia (platelet count <75 × 109/L) were randomly assigned (1:1) to receive oral hetrombopag at an initial dose of 7.5 mg once daily or a matching placebo. The primary endpoint was the proportion of treatment responders, defined as patients resuming chemotherapy within 14 days (platelet count ⩾100 × 109/L) and not requiring a chemotherapy dose reduction of ⩾15% or a delay of ⩾4 days or rescue therapy for two consecutive cycles. Results: Between 9 October 2021 and 5 May 2022, 60 patients were randomized, with 59 receiving ⩾1 dose of assigned treatment (hetrombopag/placebo arm, n = 28/31). The proportion of treatment responders was significantly higher in the hetrombopag arm than in the placebo arm [60.7% (17/28) versus 12.9% (4/31); difference of proportion: 47.6% (95% confidence interval (CI): 26.0–69.3); odds ratio = 10.44 (95% CI: 2.82–38.65); p value (nominal) based on the Cochran–Mantel–Haenszel: <0.001)]. During the double-blind treatment period, grade 3 or higher adverse events (AEs) occurred in 35.7% (10/28) of patients with hetrombopag and 38.7% (12/31) of patients on placebo. The most common grade 3 or higher AEs were decreased neutrophil count [35.7% (10/28) versus 35.5% (11/31)] and decreased white blood cell count [17.9% (5/28) versus 19.4% (6/31)]. Serious AEs were reported in 3.6% (1/28) of patients with hetrombopag and 9.7% (3/31) of patients with placebo. Conclusion: Hetrombopag is an effective and well-tolerated alternative for managing CIT in patients with solid tumors. Trial registration: ClinicalTrials.gov identifier: NCT03976882. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Author

Xu, Jianming, Shen, Lin, Zhou, Zhiwei, Li, Jie, Bai, Chunmei, Chi, Yihebali, Li, Zhiping, Xu, Nong, Li, Enxiao, Liu, Tianshu, Bai, Yuxian, Yuan, Ying, Li, Xingya, Wang, Xiuwen, Chen, Jia, Ying, Jieer, Yu, Xianjun, Qin, Shukui, Yuan, Xianglin, Zhang, Tao, Deng, Yanhong, Xiu, Dianrong, Cheng, Ying, Tao, Min, Jia, Ru, Wang, Wei, Li, Jing, Fan, Songhua, Peng, Mengye, and Su, Weiguo

Published
2020
Full Text
View/download PDF

47. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Author

Xu, Jianming, Shen, Lin, Bai, Chunmei, Wang, Wei, Li, Jie, Yu, Xianjun, Li, Zhiping, Li, Enxiao, Yuan, Xianglin, Chi, Yihebali, Yin, Yongmei, Lou, Wenhui, Xu, Nong, Bai, Yuxian, Zhang, Tao, Xiu, Dianrong, Wang, Xiuwen, Yuan, Ying, Chen, Jia, Qin, Shukui, Jia, Ru, Lu, Ming, Cheng, Yuejuan, Zhou, Zhiwei, Li, Jing, He, James, and Su, Weiguo

Published
2020
Full Text
View/download PDF

49. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Author

Luo, Suxia, Peng, Feng, Wu, Gang, Xu, Nong, Zhao, Lin, Ma, Dong, Qin, Shukui, Ren, Wei, Li, Enxiao, Lu, Hongda, Pan, Yueyin, Xiong, Jianping, Yuan, Ying, Bai, Yuxian, Chen, Lei, Hu, Yi, Zhang, Li, Gao, Yong, Huang, Jing, Xu, Jianming, Chen, Yun, Zhuang, Wu, Zhang, Yiping, Chen, Zhendong, Chen, Jia, Zhang, Helong, Niu, Zuoxing, Fan, Qingxia, Lin, Lizhu, Gu, Kangsheng, Liu, Ying, Ba, Yi, Miao, Zhanhui, Jiang, Xiaodong, Zeng, Ming, Chen, Jianhua, Fu, Zhichao, Gan, Lu, Wang, Jun, Zhan, Xianbao, Liu, Tianshu, Li, Zhiping, Shen, Lin, Shu, Yongqian, Zhang, Tao, Yang, Qing, and Zou, Jianjun

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results